Achillion Pharmaceuticals, Inc. announced that Executive Vice President Joseph Truitt has been promoted to Chief Operating Officer, a new position within Achillion. The company also announced the appointment of Avner Ingerman, M.D. as Senior Vice President and Head of Ophthalmology, also a newly created position. Mr. Truitt, who joined Achillion in 2009, will be responsible for corporate strategy and maintain his role as head of commercial and business development activities. Dr. Ingerman has more than 17 years of pharmaceutical industry experience including integral roles in the development and FDA approval of Eylea® and Lastacaft®. Dr. Ingerman was most recently Chief Clinical Officer at Ohr Pharmaceuticals since 2015.